Cover Image
市場調查報告書

C型肝炎治療藥:市場預測與分析

Hepatitis C disease forecast and market analysis to 2035 (Copy)

出版商 Datamonitor Healthcare 商品編碼 603992
出版日期 內容資訊 英文 618 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎治療藥:市場預測與分析 Hepatitis C disease forecast and market analysis to 2035 (Copy)
出版日期: 2018年01月17日 內容資訊: 英文 618 Pages
簡介

本報告提供C型肝炎治療藥市場相關調查分析,提供市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:C型肝炎治療藥

  • 摘要整理
  • 市場動態
  • 預測與未來趨勢
  • 市場定義·手法
  • 一次調查手法
  • 參考文獻
  • 產品簡介:DAKLINZA
  • 產品簡介:EPCLUSA
  • 產品簡介:HARVONI
  • 產品簡介:MAVYRET
  • 產品簡介:SOVALDI
  • 產品簡介:VIEKIRA PAK FRANCHISE
  • 產品簡介:VOSEVI
  • 產品簡介:XIMENCY
  • 產品簡介:ZEPATIER

治療:C型肝炎

  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求

流行病學:美國,日本,EU5個國家的C型肝炎

  • 摘要整理
  • 疾病概要
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優勢與法規
  • 參考文獻

上市藥:C型肝炎治療藥

  • 摘要整理
  • 產品概要
  • 產品簡介:DAKLINZA
  • 產品簡介:EPCLUSA
  • 產品簡介:HARVONI
  • 產品簡介:MAVYRET
  • 產品簡介:SOVALDI
  • 產品簡介:VIEKIRA PAK FRANCHISE
  • 產品簡介:VOSEVI
  • 產品簡介:XIMENCY
  • 產品簡介:ZEPATIER

C型肝炎治療藥的價格,給付,取用

  • 摘要整理
  • 法規標籤
  • 保險者的典型
  • 最近的銷售產品·開發中產品的取用
  • 證據要件與未來的開發平台潛在性
  • 美國的價格
  • 美國的給付
  • 日本
  • EU5大市場價格
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 手法

開發平台:C型肝炎治療藥

  • 摘要整理
  • 開發平台趨勢
目錄
Product Code: DMKC5260

Disease Overview

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Market Snapshot

Falling disease prevalence and anticipated price decreases as competition intensifies will drive a net decline in market value.

Harvoni remains the dominant option for GT-1/4 patients, but has ceded share to cheaper rivals as competition intensifies.

Cases are expected to decline, driven by complexities in high-risk populations, demographics, and treatment developments.

Mavyret's approval at a substantial discount to Epclusa paves the way for a further decline in Gilead's HCV revenues.

Lack of unmet need and declining market value prompts Johnson & Johnson and Merck & Co to discontinue pipeline regimens.

Pricing is the key differentiator for drugs in this market.

Table of Contents

  • FORECAST: HEPATITIS C (Published on 06 November 2017)
  • EXECUTIVE SUMMARY
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: DAKLINZA
  • PRODUCT PROFILE: EPCLUSA
  • PRODUCT PROFILE: HARVONI
  • PRODUCT PROFILE: MAVYRET
  • PRODUCT PROFILE: SOVALDI
  • PRODUCT PROFILE: VIEKIRA PAK FRANCHISE
  • PRODUCT PROFILE: VOSEVI
  • PRODUCT PROFILE: XIMENCY
  • PRODUCT PROFILE: ZEPATIER
  • TREATMENT: HEPATITIS C (Published on 10 January 2018)
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN HEPATITIS C
  • EPIDEMIOLOGY: HEPATITIS C IN THE US, JAPAN, AND 5EU (Published on 08 November 2017)
  • EXECUTIVE SUMMARY
  • DISEASE OVERVIEW
  • SOURCES AND METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • MARKETED DRUGS: HEPATITIS C (Published on 06 November 2017)
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: DAKLINZA
  • PRODUCT PROFILE: EPCLUSA
  • PRODUCT PROFILE: HARVONI
  • PRODUCT PROFILE: MAVYRET
  • PRODUCT PROFILE: SOVALDI
  • PRODUCT PROFILE: VIEKIRA PAK FRANCHISE
  • PRODUCT PROFILE: VOSEVI
  • PRODUCT PROFILE: XIMENCY
  • PRODUCT PROFILE: ZEPATIER
  • HEPATITIS C PRICING, REIMBURSEMENT, AND ACCESS (Published on 29 August 2017)
  • EXECUTIVE SUMMARY
  • REGULATORY LABELS
  • PAYER ARCHETYPES
  • ACCESS TO RECENTLY LAUNCHED AND PIPELINE PRODUCTS
  • EVIDENTIARY REQUIREMENTS AND FUTURE PIPELINE POTENTIAL
  • US PRICING
  • US REIMBURSEMENT
  • JAPAN
  • PRICING IN THE FIVE MAJOR EU MARKETS
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY
  • PIPELINE: HEPATITIS C (Published on 06 November 2017)
  • EXECUTIVE SUMMARY
  • PIPELINE TRENDS

LIST OF FIGURES

  • Figure 1: Hepatitis C - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's drug assessment summary of key marketed brands for hepatitis C
  • Figure 3: Total market sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Hepatitis C market value in the US, 2017-26
  • Figure 5: Hepatitis C market value in Japan, 2017-26
  • Figure 6: Japanese sales for GT-2 hepatitis C, by brand, 2017-26
  • Figure 7: Hepatitis C sales in the five major EU markets, by country, 2017-26
  • Figure 8: Total treated patient numbers for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 9: Hepatitis C sales across the US, Japan, and five major EU markets, by company, 2017-26
  • Figure 10: Hepatitis C sales of key brands in the US, Japan, and five major EU markets, 2017-26
  • Figure 11: Patient-based forecast methodology for hepatitis C
  • Figure 12: Methodology for adjusting the hepatitis C prevalent population for drug cure rates
  • Figure 13: Price sources and calculations, by country
  • Figure 14: Daklinza for hepatitis C - SWOT analysis
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • Figure 16: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • Figure 17: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 18: Epclusa for hepatitis C - SWOT analysis
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • Figure 20: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • Figure 21: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 22: Harvoni for hepatitis C - SWOT analysis
  • Figure 23: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • Figure 24: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • Figure 25: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 26: Mavyret for hepatitis C - SWOT analysis
  • Figure 27: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • Figure 28: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • Figure 29: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 30: Sovaldi for hepatitis C - SWOT analysis
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • Figure 32: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • Figure 33: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 34: Viekira Pak franchise for hepatitis C - SWOT analysis
  • Figure 35: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • Figure 36: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • Figure 37: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • Figure 38: Viekira XR sales for hepatitis C in the US, 2017-26
  • Figure 39: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 40: Vosevi for hepatitis C - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • Figure 43: Vosevi sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • Figure 44: Ximency for hepatitis C - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • Figure 47: Ximency sales for hepatitis C in Japan, 2017-26
  • Figure 48: Zepatier for hepatitis C - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • Figure 51: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 52: Percentage of chronic hepatitis C prevalent population who are diagnosed in the US, Japan, and five major EU markets, by country
  • Figure 53: Percentage of the hepatitis C diagnosed population under physician care in the US, Japan, and five major EU markets, by country
  • Figure 54: Prevalence of hepatitis C genotypes across the US, Japan, and five major EU markets, by country
  • Figure 55: Treatment status of hepatitis C patients under specialist care in the US, Japan, and five major EU markets, by country (2017)
  • Figure 56: Treatment status of hepatitis C patients under specialist care in the US, Japan, and five major EU markets, by country (2015)
  • Figure 57: Breakdown of pharmacologically treated chronic hepatitis C patients in the US, Japan, and five major EU markets by line of therapy, by country
  • Figure 58: Top four brands of each analyzed market used for the treatment of GT-1 first-line hepatitis C patients, by country
  • Figure 59: Top five brands of each analyzed market used for the treatment of GT-1 second-line and beyond hepatitis C patients, by country
  • Figure 60: Top four brands of each analyzed market used for the treatment of GT-2 first-line hepatitis C patients, by country
  • Figure 61: Top four brands of each analyzed market used for the treatment of GT-2 second-line and beyond hepatitis C patients, by country
  • Figure 62: Top four regimens of each analyzed market used for the treatment of GT-3 first-line hepatitis C patients, by country
  • Figure 63: Top four brands of each analyzed market used for the treatment of GT-3 first-line hepatitis C patients, by country
  • Figure 64: Top five brands of each analyzed market used for the treatment of GT-4 first-line hepatitis C patients, by country
  • Figure 65: Methodology for adjusting hepatitis C prevalent population for drug cure rates
  • Figure 66: Trends in total hepatitis C prevalent cases in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 67: Absolute growth in total hepatitis C prevalent cases in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 68: Trends in chronic hepatitis C prevalent cases after adjusting for treatment and cure in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 69: Daklinza for hepatitis C - SWOT analysis
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • Figure 72: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 73: Epclusa for hepatitis C - SWOT analysis
  • Figure 74: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • Figure 76: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 77: Harvoni for hepatitis C - SWOT analysis
  • Figure 78: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • Figure 80: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 81: Mavyret for hepatitis C - SWOT analysis
  • Figure 82: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • Figure 83: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • Figure 84: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 85: Sovaldi for hepatitis C - SWOT analysis
  • Figure 86: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • Figure 87: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • Figure 88: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 89: Viekira Pak franchise for hepatitis C - SWOT analysis
  • Figure 90: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • Figure 91: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • Figure 92: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • Figure 93: Viekira XR sales for hepatitis C in the US, 2017-26
  • Figure 94: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 95: Vosevi for hepatitis C - SWOT analysis
  • Figure 96: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • Figure 97: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • Figure 98: Vosevi sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • Figure 99: Ximency for hepatitis C - SWOT analysis
  • Figure 100: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • Figure 101: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • Figure 102: Ximency sales for hepatitis C in Japan, 2017-26
  • Figure 103: Zepatier for hepatitis C - SWOT analysis
  • Figure 104: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • Figure 105: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • Figure 106: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 107: Pricing of key marketed hepatitis C drugs in the five major EU markets, by country
  • Figure 108: Price sources and calculations, by country

LIST OF TABLES

  • Table 1: Total market sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 2: Hepatitis C market value in the US ($m), 2017-26
  • Table 3: Hepatitis C market value in Japan ($m), 2017-26
  • Table 4: Japanese sales for GT-2 hepatitis C, by brand ($m), 2017-26
  • Table 5: Hepatitis C sales in the five major EU markets, by country ($m), 2017-26
  • Table 6: Total treated patient numbers for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 7: Hepatitis C sales across the US, Japan, and five major EU markets, by company ($m), 2017-26
  • Table 8: Hepatitis C sales of key brands in the US, Japan, and five major EU markets ($m), 2017-26
  • Table 9: Summary of drug classes and molecules in Datamonitor Healthcare's chronic hepatitis C patient-based forecast
  • Table 10: Exchange rates used for calculating prices
  • Table 11: Gastroenterologists, hepatologists, and infectious disease specialists surveyed for the hepatitis C primary research study, 2017
  • Table 12: Daklinza drug profile
  • Table 13: Pivotal studies supporting approvals of Daklinza
  • Table 14: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 15: Epclusa drug profile
  • Table 16: Pivotal studies supporting approvals of Epclusa
  • Table 17: Epclusa late-phase trial data in hepatitis C
  • Table 18: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 19: Harvoni drug profile
  • Table 20: Pivotal studies supporting approvals of Harvoni
  • Table 21: Ongoing studies of Harvoni
  • Table 22: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 23: Mavyret drug profile
  • Table 24: Pivotal Phase III studies of Mavyret in hepatitis C
  • Table 25: Other Phase III studies of Mavyret in hepatitis C
  • Table 26: Mavyret ongoing Phase III trials in hepatitis C
  • Table 27: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 28: Sovaldi drug profile
  • Table 29: Pivotal studies supporting approvals of Sovaldi
  • Table 30: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 31: Viekira Pak franchise drug profile
  • Table 32: Pivotal studies supporting approvals of the Viekira Pak franchise
  • Table 33: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • Table 34: Viekira XR sales for hepatitis C in the US ($m), 2017-26
  • Table 35: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 36: Vosevi drug profile
  • Table 37: Pivotal Phase III trials of Vosevi for chronic hepatitis C infection
  • Table 38: Vosevi sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • Table 39: Ximency drug profile
  • Table 40: Key Phase III studies of Ximency in hepatitis C
  • Table 41: Ximency sales for hepatitis C in Japan ($m), 2017-26
  • Table 42: Zepatier drug profile
  • Table 43: Pivotal studies supporting approvals of Zepatier
  • Table 44: Zepatier late-phase trial data in hepatitis C
  • Table 45: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 46: Gastroenterologists, hepatologists, and infectious disease specialists surveyed for the hepatitis C primary research study, 2017
  • Table 47: Interpretation of results from hepatitis C screening assays
  • Table 48: Prevalence of hepatitis C genotypes across the US, Japan, and five major EU markets, by country
  • Table 49: METAVIR fibrosis scores of patients under specialist care in the US, Japan, and five major EU markets, by country
  • Table 50: Reasons for not receiving hepatitis C treatment in the US, Japan, and five major EU markets, by country
  • Table 51: Treatments available for hepatitis C across the US, Japan, and five major EU markets
  • Table 52: Summary of "recommended" treatment options for newly diagnosed patients in AASLD and EASL treatment guidelines
  • Table 53: Relative importance of unmet needs in hepatitis C treatment in the US, Japan, and five major EU markets, by country
  • Table 54: Sources used for hepatitis C analysis in the US, Japan, and five major EU markets
  • Table 55: Total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 56: Age-specific total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2016
  • Table 57: Gender-specific total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2016
  • Table 58: Hepatitis C virus genotype distributions across the US, Japan, and five major EU markets, by country, 2016
  • Table 59: Total prevalent cases of hepatitis C, by genotype, across the US, Japan, and five major EU markets, by country, 2016
  • Table 60: Treatment- and cure-adjusted total prevalent cases of chronic hepatitis C in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 61: Validation of total chronic hepatitis C forecast estimates against benchmark estimates, by country, 2016
  • Table 62: Profiled key marketed drugs for hepatitis c
  • Table 63: Daklinza drug profile
  • Table 64: Pivotal studies supporting approvals of Daklinza
  • Table 65: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 66: Epclusa drug profile
  • Table 67: Pivotal studies supporting approvals of Epclusa
  • Table 68: Epclusa late-phase trial data in hepatitis C
  • Table 69: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 70: Harvoni drug profile
  • Table 71: Pivotal studies supporting approvals of Harvoni
  • Table 72: Ongoing studies of Harvoni
  • Table 73: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 74: Mavyret drug profile
  • Table 75: Pivotal Phase III studies of Mavyret in hepatitis C
  • Table 76: Other Phase III studies of Mavyret in hepatitis C
  • Table 77: Mavyret ongoing Phase III trials in hepatitis C
  • Table 78: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 79: Sovaldi drug profile
  • Table 80: Pivotal studies supporting approvals of Sovaldi
  • Table 81: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 82: Viekira Pak franchise drug profile
  • Table 83: Pivotal studies supporting approvals of the Viekira Pak franchise
  • Table 84: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • Table 85: Viekira XR sales for hepatitis C in the US ($m), 2017-26
  • Table 86: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 87: Vosevi drug profile
  • Table 88: Pivotal Phase III trials of Vosevi for chronic hepatitis C infection
  • Table 89: Vosevi sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • Table 90: Ximency drug profile
  • Table 91: Key Phase III studies of Ximency in hepatitis C
  • Table 92: Ximency sales for hepatitis C in Japan ($m), 2017-26
  • Table 93: Zepatier drug profile
  • Table 94: Pivotal studies supporting approvals of Zepatier
  • Table 95: Zepatier late-phase trial data in hepatitis C
  • Table 96: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 97: Approved labels for marketed hepatitis C drugs in the US, Japan, and five major EU markets
  • Table 98: Initial cost-containment measures utilized to manage the budget impact of hepatitis C drugs in the US and five major EU markets
  • Table 99: Current cost-containment measures utilized to manage the budget impact of hepatitis C drugs in the US and five major EU markets
  • Table 100: Levers impacting access to hepatitis C drugs in the US and five major EU markets
  • Table 101: US pricing of key marketed drugs
  • Table 102: Prior authorization criteria for hepatitis C agents in six major health plans
  • Table 103: Formulary placement of hepatitis C agents in selected commercial formularies
  • Table 104: Formulary placement of hepatitis C agents in selected 2017 Medicare Part D formularies
  • Table 105: Formulary placement of hepatitis C medications in selected Medicaid state preferred drug lists
  • Table 106: Pricing of key marketed hepatitis C drugs in Japan
  • Table 107: Pricing of key hepatitis C drugs in Japan
  • Table 108: Transparency Committee's ASMR ratings and pricing implications
  • Table 109: Transparency Committee's SMR ratings and pricing implications
  • Table 110: Transparency Committee's assessment of hepatitis C treatments
  • Table 111: G-BA assessment of Sovaldi
  • Table 112: G-BA assessment of Olysio
  • Table 113: G-BA assessment of Daklinza
  • Table 114: G-BA assessment of Harvoni
  • Table 115: G-BA assessment of Viekirax ± Exviera
  • Table 116: G-BA assessment of Epclusa
  • Table 117: IQWiG assessment of Zepatier
  • Table 118: AIFA's reimbursement decisions for hepatitis C agents in Italy
  • Table 119: Local formulary decisions for hepatitis C agents
  • Table 120: Therapeutic positioning reports for hepatitis C agents in Spain
  • Table 121: Spanish Society of Hospital Pharmacy ratings
  • Table 122: GENESIS-SEFH assessment of hepatitis C treatments
  • Table 123: NICE assessments for hepatitis C therapies
  • Table 124: SMC assessments for hepatitis C therapies
  • Table 125: Exchange rates used for calculating branded drug prices
Back to Top